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Summary
The inhibition of KSP causes mitotic arrest by activating the spindle assembly checkpoint. While transient inhibition of
KSP leads to reversible mitotic arrest, prolonged exposure to a KSP inhibitor induces apoptosis. Induction of apoptosis
by the KSP inhibitor couples with mitotic slippage. Slippage-refractory cells show resistance to KSP inhibitor-mediated
lethality, whereas promotion of slippage after mitotic arrest enhances apoptosis. However, attenuation of the spindle
checkpoint confers resistance to KSP inhibitor-induced apoptosis. Furthermore, sustained KSP inhibition activates the
proapoptotic protein, Bax, and both activation of the spindle checkpoint and subsequent mitotic slippage are required for
Bax activation. These studies indicate that in response to KSP inhibition, activation of the spindle checkpoint followed by
mitotic slippage initiates apoptosis by activating Bax.S I G N I F I C A N C E
KSP inhibitors are novel antimitotic agents that have entered clinical trials for cancer therapy. We show that sustained activation of
the spindle checkpoint by a KSP antagonist, followed by mitotic slippage, activates Bax and initiates apoptosis. Both spindle check-
point-deficient and mitotic slippage-refractory cells are resistant to KSP inhibitor-induced Bax activation and apoptosis. Sequential
suppression of Cdk1 synergizes with the KSP inhibitor in inducing cell death by facilitating mitotic slippage in spindle checkpoint-
competent cells. These results delineate the critical events that mediate the lethality of KSP inhibitors and provide clues on the
identification of KSP inhibitor-resistant tumors and the selection of adjunct agents that may enhance the efficacy of KSP inhibitors.Introduction
The mitotic spindle is a pharmaceutically validated target for
cancer therapeutics (Wood et al., 2001). Antispindle agents,
such as taxanes and vinca alkaloids, which interfere with
microtubule dynamics by targeting tubulin, have been widely
used in the clinic for the treatment of human malignancies (Jor-
dan and Wilson, 2004). However, since microtubules are not
only essential for mitosis, but also required for other critical
physiological functions, such as intracellular transport and or-
ganelle positioning, the microtubule inhibitors act on both pro-
liferating and postmitotic cells and exhibit microtubule-depen-
dent side effects, including peripheral neuropathy (Rowinsky et
al., 1993; Tuxen and Hansen, 1994). Thus, agents that target
the mitotic spindle via a novel mechanism of action and with
greater specificity toward tumors are desired for the treatment
of human neoplasm.
KSP (hsEg5, kinesin-5) is a mitotic spindle motor protein be-
longing to the kinesin superfamily (Vale and Fletterick, 1997;
Dagenbach and Endow, 2004) that plays an essential role in
centrosome separation and in the formation of a bipolar mitotic
spindle (Enos and Morris, 1990; Blangy et al., 1995; Sawin and
Mitchison, 1995). Inhibition of KSP function led to cell cycle
arrest in mitosis with the formation of monopolar mitotic spin-CANCER CELL : JULY 2005 · VOL. 8 · COPYRIGHT © 2005 ELSEVIER INC.dles (Blangy et al., 1995; Mayer et al., 1999; Kapoor et al.,
2000). A small molecule inhibitor of KSP exhibited antitumor
activity superior to that of paclitaxel in a human tumor xeno-
graft model (Sakowicz et al., 2004). Since KSP functions exclu-
sively in mitosis, inhibitors of this mitotic kinesin should lack
the liability of tubulin-targeting agents and act specifically on
proliferating cells. In addition, they should be effective in tax-
ane-resistant tumors, where the resistance results from muta-
tions on β-tubulin (Monzo et al., 1999) or alterations in the ex-
pression of tubulin isoforms (Hasegawa et al., 2003). Indeed,
KSP inhibitors have recently entered clinical trials for cancer
therapy.
Since KSP inhibitors are being developed as a new genera-
tion of antimitotic agents that antagonize a novel target, an in-
depth understanding of their biological mechanism of action in
cancer cells is warranted and could provide insights into the
effective development of these agents in the clinic. Early
studies in Xenopus egg extracts and mammalian cells showed
that the suppression of KSP activity induced the formation of
monoastral spindles and provoked the activation of the spindle
assembly checkpoint (Sawin et al., 1992; Blangy et al., 1995;
Mayer et al., 1999; Kapoor et al., 2000). The spindle assembly
checkpoint or mitotic checkpoint is a signaling pathway with
multiple components, including Mps1, Bub1, BubR1, Bub3,DOI 10.1016/j.ccr.2005.06.003 49
A R T I C L EMad1, and Mad2, etc., that monitors the proper attachment
of microtubules to kinetochores and the tension between the
kinetochores of sister chromatids to ensure a faithful separa-
tion of chromosomes during cell division (Musacchio and Hard-
wick, 2002; Bharadwaj and Yu, 2004). The activated spindle
checkpoint arrests cells at metaphase by preventing the onset
of anaphase. However, a number of important issues regarding
cellular responses to KSP inhibition remain unaddressed. For
instance, what is the fate of cells arrested in mitosis by the
inhibition of KSP, and what is the role of the spindle checkpoint
in cellular responses to KSP inhibitors?
Using a potent, specific, and cell-permeable small molecule
inhibitor of KSP, we characterized cellular responses to KSP
inhibition in cancer cell lines and investigated the role of the
spindle checkpoint in the induction of apoptosis by a KSP in-
hibitor. Previous studies with microtubule inhibitors indicate
that in the presence of persistent spindle damages, cells
eventually exit mitosis in the absence of chromosome segrega-
tion and cytokinesis, resulting in tetraploid cells in a pseudo-
G1 phase (Minn et al., 1996; Lanni and Jacks, 1998). This pro-
cess is termed mitotic slippage. Mitotic slippage could occur
in both spindle checkpoint-deficient and -proficient cells. While
cells with deficient spindle checkpoint slip out of mitosis rap-
idly without mitotic block or after milder mitotic arrest, spindle
checkpoint-proficient cells undergo mitotic slippage after pro-
longed mitotic arrest by overriding an activated spindle check-
point (Minn et al., 1996; Cahill et al., 1998; Lanni and Jacks,
1998; Michel et al., 2001). The latter is also termed the adapta-
tion of the spindle checkpoint. We show here that induction of
apoptosis by a KSP inhibitor requires both activation of the
spindle checkpoint and subsequent mitotic slippage. In spindle
checkpoint-competent cells, initiation of apoptosis is coupled
with mitotic slippage. Slippage-refractory cells are resistant to
KSP antagonist-induced apoptosis despite prolonged activa-
tion of the spindle checkpoint, whereas promotion of mitotic
slippage greatly enhances apoptosis. However, cells with
weakened spindle checkpoint incur less apoptosis than the
spindle checkpoint-proficient counterparts after exposure to a
KSP inhibitor, indicating that mitotic slippage alone without ac-
tivation of the spindle checkpoint is not sufficient to induce
apoptosis. Thus, mitotic slippage by breaching the activated
spindle checkpoint is responsible for the induction of cell sui-
cide. Furthermore, activation of the spindle checkpoint fol-
lowed by mitotic slippage is required for the activation of Bax,
a proapoptotic member of the Bcl-2 family (Cory and Adams,
2002). Based on these results, we propose a molecular frame-
work that mediates cellular responses to KSP inhibitors and
discuss implications for the development of these agents in
the clinic.
Results
Identification and characterization of KSP-IA, a potent
and specific inhibitor of KSP
Like other kinesins, KSP contains a conserved motor domain
that catalyses hydrolysis of ATP and generates a directed me-
chanical force along the microtubule (Yang et al., 1990). This
ATPase activity of KSP is essential for the formation of spindle
bipolarity in mitosis. Using a recombinant KSP motor domain,
a high-throughput screen was employed to identify inhibitors of
KSP ATPase activity. From an initial screening lead, structure-50activity relationships were established, which led to the identifi-
cation of a potent and specific inhibitor of KSP, KSP-IA, that
contains a dihydropyrrole core structure (Figure 1A). KSP-IA is
an allosteric inhibitor of KSP with an IC50 of 11 nM, which nei-
ther competes with ATP nor interferes with microtubule poly-
merization. While potently suppressing KSP, KSP-IA has no in-
hibitory activity toward other kinesins, including the mitotic
kinesins CENP-E and MKLP-1, the neuronal kinesin KIF-3A,
and uKHC (IC50s > 50 M). As expected, KSP-IA recapitulated
the biological activities of other KSP-inhibitory agents, such as
a neutralizing antibody against KSP (Sawin et al., 1992; Blangy
et al., 1995) and the small molecule inhibitor, monastrol (Mayer
et al., 1999; Kapoor et al., 2000). KSP-IA induced the formation
of monoastral spindles, a radial array of microtubules sur-
rounded by a ring of chromosomes, in cultured A2780 ovarian
carcinoma cells (Figure 1B), and activated the spindle check-
point as determined by detection of the phosphorylation of
BubR1 (p-BubR1) (Figure 1C). BubR1 is a component of the
spindle checkpoint pathway that is phosphorylated during
spindle checkpoint activation (Li et al., 1999). KSP-IA caused
mitotic arrest in a dose-dependent manner, with an EC50 of 30
nM after a treatment for 16 hr by measurement of cellular DNA
content using fluorescence-activated cell sorting (FACS) (Fig-
ure 1D). KSP-IA-induced mitotic arrest was further confirmed
by measuring the fraction of cells stained by a mitosis-specific
antibody, MPM-2 (Davis et al., 1983) (Figure 1E). Similar results
were obtained in other human cancer cell lines, including the
colon cancer cell line HCT116. Thus, KSP-IA is a potent, spe-
cific, and cell-active inhibitor of KSP, and it can be used to
investigate the biological consequence of KSP inhibition.Figure 1. Chemical structure and biological activities of KSP-IA
A: Chemical structure of KSP-IA.
B and C: KSP-IA induces the formation of monopolar mitotic spindle and
activates the spindle checkpoint in A2780 cells. After treatment with vehi-
cle (DMSO) or KSP-IA (300 nM) for 16 hr, the mitotic spindle (green) and
chromosomes (blue) were visualized by immunofluorescence microscopy
(B) and the phosphorylation of BubR1 was detected by Western blot (C).
D and E: KSP-IA induces mitotic arrest in A2780 cells. After treatment with
vehicle or KSP-IA for 16 hr, cells were analyzed for DNA content (D) and
MPM2 antibody staining (E) by FACS.CANCER CELL : JULY 2005
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checkpoint-competent cells: Reversible mitotic arrest
versus commitment to apoptosis
To determine the fate of cells arrested in mitosis due to KSP
inhibition, spindle checkpoint-intact HCT116 cells were treated
with KSP-IA for various times at 300 nM, a concentration that
caused maximum percentage of cells arrested in mitosis after
16 hr treatment, and then either harvested immediately or al-
lowed to incubate in the absence of compound for additional
24 hr prior to harvest. Mitotic arrest and apoptosis were moni-
tored by FACS analysis to measure DNA content. Following 12
hr exposure to KSP-IA, the majority of cells (85%) were ar-
rested in G2/M containing 4N DNA, with few, if any, cells in
sub-G1, which is indicative of apoptosis (Figure 2A). After a
further incubation for 24 hr in drug-free medium, most of the
arrested cells re-entered the cell cycle and few apoptotic cells
(2%) were observed (Figure 2A). While extending the time of
drug treatment to 24 hr resulted in a similar percentage of tet-
raploid cells (86%) with few sub-G1 cells, a significant fraction
of subdiploid cells (25%) appeared following a further incuba-
tion for 24 hr in the absence of KSP-IA (Figure 2B), indicating
that 24 hr compound exposure committed a significant portion
of cells to apoptosis.
The detection of sub-G1 cells only after a further incubation
in drug-free medium, but not immediately after 24 hr com-
pound treatment, may be due to the fact that the sub-G1 frac-
tion of cells results from DNA fragmentation, which occurs at
a late stage of apoptosis. Indeed, 48 hr treatment with KSP-IA
without a further incubation led to a comparable fraction of
subdiploid cells (26%), suggesting that this time interval is suf-
ficient for cells to achieve both mitotic arrest and apoptotic DNA
fragmentation. In addition, a robust activation of caspase-3, anFigure 2. Time-dependent effects of KSP inhibition: Reversible mitotic arrest
versus apoptosis
HCT116 cells were treated with KSP-IA (300 nM) for 12 or 24 hr, and either
harvested immediately (gray open plots) or incubated for another 24 hr in
drug-free medium prior to harvesting (black solid plots). Cells were ana-
lyzed for DNA content by FACS. The histograms of cell number versus DNA
content are presented.CANCER CELL : JULY 2005early event during apoptosis, was detected immediately after
24 hr compound treatment (Figure 3), and z-VAD, a pan-cas-
pase inhibitor, completely blocked KSP-IA-induced cell death
(Supplemental Figure S1). This further supports that prolonged
exposure to KSP-IA induces caspase-dependent apoptosis.
Similar results were obtained in A2780 cells (data not
shown). Together, the data suggest that in spindle checkpoint-
competent cells, transient KSP inhibition only causes revers-
ible mitotic arrest, and that a prolonged inhibitor treatment or
a sustained mitotic arrest is required to initiate apoptosis.
Induction of apoptosis by KSP-IA is coupled with mitotic
slippage in spindle checkpoint-competent cells
KSP-IA causes mitotic arrest by activating the spindle check-
point (Figures 1C–1E). Since spindle checkpoint-competent cells
undergo mitotic slippage after sustained spindle damage and
KSP-IA only induces apoptosis after prolonged compound
treatment, we investigated the possible link between mitotic
slippage and apoptosis. To reduce the temporal heterogeneity
in the entry into mitosis and in the duration of mitotic arrest
among asynchronous cells, HCT116 cells were synchronized
at the boundary of G1 and S phases by double thymidine
block, and then incubated in the presence of KSP-IA for vari-
ous times upon release from thymidine block. Cells were either
harvested immediately after compound treatment or incubated
for another 24 hr in drug-free medium, and then analyzed for
cell cycle distribution, mitotic slippage, and apoptosis. Follow-Figure 3. Temporal coupling of KSP-IA-induced apoptosis and mitotic slip-
page in HCT116 cells
Cells were synchronized at G1/S boundary by double thymidine block.
Upon release from the block (0 hr), cells were treated with either vehicle
or KSP-IA (300 nM) for various times. Cells, collected immediately after drug
treatment, were analyzed for DNA content by FACS, steady-state levels of
p-nucleolin, cyclin E, and GAPDH by Western blot, and caspase-3 activity.
Caspase-3 activity was determined in triplicate, and bars indicate stan-
dard deviation (SD). The data are representative of three similar experi-
ments.51
A R T I C L Eing double thymidine block, the majority of HCT116 cells (90%)
were synchronized at the late G1 phase with 2N DNA content
and a high level of cyclin E, whose expression peaks in the late
G1 phase (Sherr, 1996) (Figure 3). Upon release from thymidine
block, both vehicle-treated and KSP-IA-treated cells displayed
comparable kinetics of progression through the S and G2
phases (Supplemental Figure S2), indicating that the inhibition
of KSP did not affect cell cycle progression through S and G2
phases. However, 12 hr post release from thymidine block,
cells incubated with KSP-IA were arrested in mitosis (92%)
with 4N DNA content and an increase of mitosis-specific phos-
phorylation of nucleolin (p-nucleolin) (Srivastava and Pollard,
1999), in contrast to vehicle-treated cells which had passed
through mitosis (Figure 3). At this time, no activation of cas-
pase-3 was detected (Figure 3), and if the compound was re-
moved, 24 hr later, the arrested cells returned to the cell cycle
with only 4% sub-G1 cells, indicating a reversible mitotic ar-
rest. Strikingly, 24 hr post release from thymidine block and
exposure to KSP-IA, a similar percentage of cells (88%) re-
mained in tetraploidy (4N DNA) with few apoptotic cells, but
the mitotic marker (p-nucleolin) disappeared, indicating that
the arrested cells had undergone mitotic slippage (Figure 3). At
the same time, robust activation of caspase-3 was detected
(Figure 3). If the compound was removed at this time (after 24
hr drug treatment), 26% sub-G1 cells were detected after a
further incubation for 24 hr. This suggests that following pro-
longed KSP inhibition, apoptosis was initiated, coupling with
mitotic slippage.
If the induction of apoptosis by KSP-IA depends on mitotic
slippage, an absence or delay of mitotic slippage should pre-
vent or delay apoptosis. In a screen of cell lines for differential
sensitivities to the inhibition of KSP, the colon cancer cell line
HT29 was identified as resistant to KSP-IA-induced apoptosis.
While 48 hr incubation with KSP-IA caused 25%–30% of
HCT116 or A2780 cells to die, only 2% of HT29 cells un-
derwent apoptosis under same conditions. This is despite the
fact that KSP-IA induced a similar extent of mitotic block in
HT29 cells. As assessed by MPM2 staining-coupled FACS
analysis, 61% HT29 cells and 59% HCT116 cells were arrested
in mitosis after treatment with KSP-IA for 16 hr. To determine
if the resistance to KSP-IA-induced apoptosis in HT29 cells
is related to mitotic slippage, synchronized HT29 cells were
exposed to KSP-IA or paclitaxel for various times upon release
from thymidine block, and harvested for determination of mi-
totic arrest, mitotic slippage, and apoptosis. Synchronous
HT29 cells progressed through S and G2 phases with compa-
rable cell cycle transition time to HCT116 cells in the presence
of KSP-IA, and then arrested in mitosis (Figure 4A and data not
shown). However, unlike HCT116 cells, 24 hr post release from
thymidine block, the majority of KSP-IA-treated HT29 cells
were still arrested in mitosis with 4N DNA content as deter-
mined by maintenance of the mitotic marker, p-nucleolin (Fig-
ure 4A). Even after 48 hr incubation with KSP-IA, HT29 cells
maintained a high level of p-nucleolin (Figure 4A), suggesting
that the majority of cells failed to undergo mitotic slippage. In
addition, neither caspase-3 activation nor subdiploid cells were
detected in HT29 cells at these time points (Figure 4A). An ex-
tension of the treatment with KSP-IA to 72 hr only resulted in
8% sub-G1 cells, whilew60% cells remained arrested in mito-
sis. If further cultured in drug-free medium for another 24 hr,
the majority of HT29 cells re-entered cell cycle (37% at G1,5226% at S, and 30% at G2/M) with few apoptotic cells (8%).
The data indicate that the death resistance of HT29 cells may
be a result of the delay or resistance to mitotic slippage. If
this is the case, promotion of mitotic slippage should enhance
apoptosis in these cells.
Although the mechanism by which cells with damaged spin-
dles escape mitotic arrest and exit mitosis remains unknown,
inactivation of the mitotic kinase Cdk1 facilitates the exit from
mitosis (Andreassen and Margolis, 1994). Thus, we tested
whether a Cdk1 inhibitor, purvalanol A (Purv) (Gray et al., 1998)
could accelerate mitotic slippage and enhance the induction of
apoptosis by KSP-IA. Synchronized HT29 cells were exposed
to KSP-IA or paclitaxel for 24 hr upon release from thymidine
block, and followed by incubation with either DMSO or Purv
for 6 or 10 hr in the absence of KSP-IA or paclitaxel. Cells were
harvested for evaluation of cell cycle distribution and mitotic
slippage. As before (Figure 4A), 24 hr exposure to KSP-IA
caused the majority of cells (92%) to arrest in mitosis with 4N
DNA and accumulation of p-nucleolin as well as the mitosis-
specific phosphorylation of histone H3 (p-histone H3) (Crosio
et al., 2002) (Figure 4B). When cells were subsequently incu-
bated in drug-free medium for 6 or 10 hr, a portion of cells
(w32%) divided and entered the G1 phase with 2N DNA, and
most cells (w60%) stayed in mitosis with appreciable levels of
p-nucleolin and p-histone H3 (Figure 4B). By contrast, when
cells were subsequently incubated with Purv for 6 hr, levels of
p-nucleolin and p-histone H3 diminished, although most cells
(78%) remained in tetraploidy (Figure 4B), indicating that Purv
promoted mitotic slippage. In addition, sequential treatment
with Purv for 10 hr resulted in an increase in subdiploid fraction
(Figure 4B), suggesting that promotion of slippage by Purv en-
hanced apoptosis. To preclude the possibility that the ob-
served enhancement of apoptosis was due to the induction of
death by Purv itself, synchronous HT29 cells were exposed to
either vehicle, KSP-IA, or paclitaxel for 24 hr, followed by a 12
hr incubation with either vehicle or Purv in the absence of KSP-
IA or paclitaxel. Cell cycle distribution and apoptosis were as-
sessed by FACS. The sequential treatment of either vehicle
followed by Purv, or KSP-IA followed by DMSO, only caused
marginal apoptosis (<5%), whereas KSP-IA followed by Purv
led to a large fraction of sub-G1 cells (20%) (Figure 4C), sug-
gesting that Purv acted synergistically with KSP-IA in inducing
apoptosis. Additional experiments revealed that the synergy
between KSP-IA and Purv was sequence-dependent; i.e., pre-
treatment with Purv failed to enhance KSP-IA-mediated apo-
ptosis (data not shown). All these results support that mitotic
slippage is required for induction of apoptosis by KSP-IA, and
that promotion of mitotic slippage in slippage-refractory cells
can enhance KSP inhibitor-mediated killing.
Similar results were obtained with paclitaxel. While 48 hr
treatment with 100 nM paclitaxel resulted in 35% sub-G1
HCT116 cells, it caused only 5% sub-G1 fraction in slippage-
refractory HT29 cells (Figure 4A). Sequential treatment with
Purv after exposure to paclitaxel promoted mitotic slippage
and greatly enhanced paclitaxel-mediated apoptosis in HT29
cells (Figures 4B and 4C), suggesting that paclitaxel-induced
apoptosis also couples with mitotic slippage in these cells.
Induction of apoptosis by KSP-IA requires activation
of the spindle assembly checkpoint
Mitotic slippage occurs in both spindle checkpoint-proficient
and -deficient cells. The former cells slip out of mitosis afterCANCER CELL : JULY 2005
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dent on mitotic slippage in HT29 cells
A: HT29 cells are refractory to mitotic slippage
and resistant to KSP-IA-induced apoptosis. Cells,
synchronized at G1/S boundary, were exposed
to vehicle, paclitaxel (100 nM), or KSP-IA (300
nM) for 24 or 48 hr upon release from thymidine
block. Harvested cells were analyzed as de-
scribed in Figure 3.
B and C: Promotion of mitotic slippage by Purv
enhances KSP-IA- and paclitaxel-induced apo-
ptosis in HT29 cells. Upon release from thymidine
block, synchronized HT29 cells were exposed to
KSP-IA or paclitaxel for 24 hr, and then treated
with either DMSO or Purv (20 M) for 6 or 10 hr
in the absence of KSP-IA or paclitaxel. Har-
vested cells were analyzed as described in Fig-
ure 3. Steady-state levels of p-histone H3 were
assessed by Western blot (B). Synchronized HT29
cells were treated with vehicle, KSP-IA, or pacli-
taxel for 24 hr, followed by incubation with either
DMSO or Pruv. for 12 hr in the absence of KSP-IA
or paclitaxel. Cells were analyzed for DNA
content by FACS (C).prolonged mitotic arrest by breaching an activated spindle
checkpoint, while the latter undergo mitotic slippage rapidly
after attenuated, if any, action of the spindle checkpoint (Minn
et al., 1996; Cahill et al., 1998; Lanni and Jacks, 1998; Michel
et al., 2001). To elucidate the role of spindle checkpoint in the
induction of apoptosis by KSP inhibitors, we generated a
HeLa-derived cell line (HNB1), where the expression of a Myc-
tagged, amino-terminal domain of human Bub1 (N-hBub1,
amino acids 1–331) can be induced by doxycycline (Figures
5A and 5E). Bub1 is an essential component of the spindle
checkpoint pathway (Musacchio and Hardwick, 2002). It has
been shown that a corresponding amino-terminal domain of mu-
rine Bub1, which shares 78% sequence similarity to N-hBub1,
suppresses the spindle checkpoint function in a dominant
negative way by competitively binding to the kinetochores of
chromosomes (Taylor and McKeon, 1997). To determine whether
N-hBub1 suppresses mitotic checkpoint and affects apoptosis
in response to KSP-IA and paclitaxel, HNB1 cells were grown
in the presence (induction of N-hBub1) or absence (noninduc-
tion of N-hBub1) of doxycycline for 24 hr, and then exposed to
KSP-IA or paclitaxel for various times. The sampled cells wereCANCER CELL : JULY 2005analyzed by FACS after staining with either the MPM2 antibody
or propidium iodide to determine mitotic index and apoptosis.
An increase in mitotic index is indicative of mitotic arrest. Addi-
tionally, activity of the spindle checkpoint was monitored by
assessing p-BubR1. Although the expression of N-hBub1 did
not affect cell progression or cell viability in the absence of
KSP-IA and paclitaxel (Figure 5B), cells expressing N-hBub1
(N-hBub1+) exhibited reduced p-BubR1, lower mitotic index,
and fewer apoptotic cells following exposure to KSP-IA (Fig-
ures 5C–5E). Consistently, after 48 hr treatment with KSP-IA,
lower caspase-3 activity was detected in cells expressing
N-hBub1 than in those without induction of N-hBub1 expression
(Supplemental Figure S3). This suggests that N-hBub1 inhib-
ited the spindle checkpoint function and attenuated KSP-
IA-induced apoptosis. The expression of N-hBub1 also inhib-
ited paclitaxel-induced mitotic arrest and cell death, although
the suppression on paclitaxel lethality is not as great as that
on KSP-IA lethality (Figures 5C and 5D). To preclude the possi-
bility that the inhibition of apoptosis by N-hBub1 is specific
to this peptide and independent of suppression of the spindle
checkpoint, we determined KSP-IA and paclitaxel-triggered53
A R T I C L EFigure 5. Suppression of the spindle checkpoint by N-hBub1 inhibits KSP-IA-
mediated apoptosis
A and B: Induction of N-hBub1 expression by doxycycline in HNB1 cell line
does not affect cell viability and cell cycle progression in the absence of
spindle inhibitors. HNB1 cells were incubated in the presence of doxycy-
cline for various times, and analyzed for steady-state levels of Myc-tagged
N-hBub1 by Western blot using an anti-Myc antibody (A) and DNA content
by FACS (B).
C and D: The expression of N-hBub1 suppresses KSP-IA- and paclitaxel-
induced mitotic arrest and apoptosis. HNB1 cells were incubated in the
absence or presence of doxycycline for 24 hr, and then treated with KSP-
IA (300 nM) or paclitaxel (100 nM) for various times. Mitotic index (C) and
apoptosis (sub-G1 cells, D) were determined by FACS. The results are repre-
sentative of three independent experiments.
E: Induction of N-hBub1 expression by doxycycline inhibits the spindle
checkpoint-dependent phosphorylation of BubR1. N-hBub1+ indicates
cells expressing N-hBub1, while N-hBub1− indicates cells with no induction
of N-hBub1 expression.apoptosis in a pair of HCT116 cell lines that are either homozy-
gous (Mad2+/+) or heterozygous (Mad2+/−) for the Mad2 gene.
Mad2 is another component of the spindle checkpoint pathway
(Musacchio and Hardwick, 2002). While HCT116 Mad2+/+ cells
have an intact spindle checkpoint, the Mad2+/− derivatives
contain a weakened checkpoint due to Mad2 haploinsuffi-
ciency (Michel et al., 2001). After exposure to KSP-IA or pacli-54taxel for various times, spindle checkpoint-deficient Mad2+/−
cells displayed a lower mitotic index and reduced apoptosis
than Mad2+/+ cells (Figures 6A and 6B), with an accumulation
of polyploid cells containing 8N DNA after 48 hr compound
treatment (Figure 6C). The differential responses to KSP inhibi-
tion between Mad2+/+ and Mad2+/− HCT116 cells were further
examined by a colony formation assay. After exposure to either
vehicle or KSP-IA for 24 hr, both Mad2+/+ and Mad2+/− cells
were incubated in the absence of the compound for 10 days
prior to counting colonies. As shown in Figure 6D, spindle
checkpoint-defective Mad2+/− cells exhibited far greater clono-
genic survival than checkpoint-competent Mad2+/+ cells after
KSP-IA treatment (Figure 6D). Similarly, inhibition of the spindle
checkpoint activity by expression of N-hBub1 in HNB1 cells
also greatly increased survival following KSP inhibition (data
not shown). These data indicate that mitotic slippage alone is
not sufficient to induce apoptosis, and that a competent spin-
dle checkpoint is required for inducing apoptosis by KSP-IA.
Prolonged inhibition of KSP activates Bax in a manner
dependent upon both activation of the spindle
checkpoint and mitotic slippage
Next, we explored the proteins that could potentially mediate
the lethality of KSP inhibitors. Bax is a proapoptotic protein of
the Bcl-2 family that mediates apoptosis in response to various
insults, including chemotherapeutic agents (Wei et al., 2001;
Cory and Adams, 2002). In healthy cells, Bax is mainly located
in the cytosol as an inactive monomer. Upon stimulation by
death signals, Bax is activated, resulting in a conformation
change that targets it to the outer membrane of the mito-
chondria where it initiates apoptosis by permeabilizing the
mitochondria membrane (Wolter et al., 1997; Hsu and Youle,
1998; Nechushtan et al., 1999). Bax activation can be moni-
tored by an immunoprecipitation-coupled Western blot analy-
sis, where the 6A7 monoclonal antibody is used to specifically
precipitate the active conformers of Bax (Hsu and Youle, 1998).
To examine whether KSP-IA induces apoptosis by activating
Bax, A2780 cells were exposed to KSP-IA for 10 or 24 hr and
then either harvested immediately or incubated for another 24
hr in the absence of compound prior to harvest. Bax activation,
caspase-3-mediated cleavage of PARP (polyADP-ribose poly-
merase), and fraction of apoptotic cells were determined. While
an exposure to KSP-IA for 10 hr failed to activate Bax and
caspase-3, and led to reversible mitotic arrest with few apo-
ptotic cells, a prolonged compound treatment (24 hr) activated
Bax and caspase-3, and induced apoptosis (Figures 7A and
7B). This suggests that KSP-IA may induce apoptosis by acti-
vating Bax.
The role of the spindle checkpoint in the activation of Bax
by KSP-IA was examined in HNB1 cells. Inhibition of mitotic
checkpoint by the expression of N-Bub1 in HNB1 cells attenu-
ated both the activation of Bax and the induction of apoptosis
(Figure 8A), indicating that activation of the spindle checkpoint
is required for KSP inhibitor-induced Bax activation. However,
as shown in Figure 7A, transient mitotic arrest by KSP-IA failed
to activate Bax, raising the question as to whether activation
of Bax is also dependent on subsequent mitotic slippage. To
address this issue, Bax activation and mitotic arrest were eval-
uated in checkpoint-intact but slippage-refractory HT29 cells
after exposure to KSP-IA followed by treatment with either
DMSO or Purv. As shown in Figure 8B, no Bax activation wasCANCER CELL : JULY 2005
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posed to KSP-IA for 24 hr followed by 4 hr incubation with
DMSO, and these cells remained arrested in mitosis as deter-
mined by maintenance of p-nucleolin and a high mitotic index
(Figure 8B). However, sequential treatment with Purv for 4 hr
after 24 hr exposure to KSP-IA promoted mitotic slippage, as
demonstrated by a high percentage of tetraploid cells with dis-
appearance of p-nucleolin and a significant reduction of mitotic
index (Figure 8B). Moreover, promotion of mitotic slippage acti-
vated Bax (Figure 8B). This suggests that Bax activation is de-
pendent on mitotic slippage as well. Together, both activation
of the spindle checkpoint and subsequent mitotic slippage are
required for activating Bax.
Discussion
Cells have evolved multifaceted surveillance mechanisms to
preserve genomic integrity. The primary function of the spindle
assembly checkpoint is to prevent errors in chromosome seg-
regation during mitosis (Bharadwaj and Yu, 2004). The inhibi-
tion of KSP causes the formation of monopolar mitotic spin-
dles, which activates the spindle checkpoint, presumably by
altering the tension exerted between the kinetochores of sister
chromatids (Kapoor et al., 2000). The activated spindle check-
point suppresses the E3 ubiquitin ligase activity of the ana-
phase-promoting complex (APC) through a cascade of signal-
ing, and prevents the onset of anaphase (Musacchio and
Hardwick, 2002; Bharadwaj and Yu, 2004). The inhibition of
KSP in cancer cells leads to distinct consequences depending
on the status of the spindle checkpoint. In checkpoint-compe-
tent cells, KSP-IA arrests cells at metaphase by activating the
spindle checkpoint (Figure 1). Transient mitotic arrest is revers-
ible, and upon removal of KSP inhibitor, cells segregate chro-
mosomes, undergo cytokinesis, and enter the next cell cycle
without induction of apoptosis (Figure 2). Prolonged KSP inhi-
bition, however, triggers cell suicide (Figures 2 and 3). This
suggests that there is a time window for arrested cells to re-
cover from spindle damage, and if the insult is persistent, the
afflicted cells are eliminated by committing to the apoptotic
program to prevent the emergence of cells with an aberrant
and unstable genome. This observation is reminiscent of the
responses of other cellular checkpoints. For instance, depend-
ing on the extent of the insult and cellular context, DNA dam-
age may cause either transient cell cycle arrest accompanied
by DNA repair, or apoptosis (Zhou and Elledge, 2000). The time
window for reversible mitotic arrest or recovery from KSP sup-
pression may be governed by the timing of mitotic slippage or
adaptation of the spindle checkpoint since, as suggested by
our studies, the induction of apoptosis is coupled with mitotic
slippage. Three lines of evidence indicate the dependence of
apoptosis on mitotic slippage in checkpoint-intact cells: (1) in
both HCT116 and A2780 cells, KSP inhibitor-induced apopto-
sis and mitotic slippage are temporally coupled (Figure 3 and
data not shown); (2) slippage-refractory HT29 cells are resistant
to the induction of apoptosis by KSP-IA (Figure 4A); and (3)
acceleration of mitotic slippage by the Cdk1 inhibitor, Purv,
promotes KSP-IA-mediated cell death in HT29 cells (Figure 4B
and 4C).
It is conceivable that abortive mitosis in the absence of chro-
mosome segregation and cytokinesis results in tetraploid G1
cells and other abnormalities, such as the presence of multipleCANCER CELL : JULY 2005Figure 6. The role of spindle checkpoint in the induction of apoptosis by
KSP-IA and paclitaxel: Effect of Mad2 haploinsufficiency
A and B: Mad2 heterozygous HCT116 cells (Mad2+/−) exhibited defective
spindle checkpoint function and lower extent of apoptosis than the check-
point-competent counterparts containing homozygous Mad2 (Mad2+/+) in
response to KSP-IA or paclitaxel. Both cell lines were treated with KSP-IA
(300 nM) or paclitaxel (100 nM) for various times, and harvested and ana-
lyzed to determine mitotic index and apoptosis as described in Figures 5C
and 5D. The data shown are representative of three similar experiments.
C: The spindle checkpoint-deficient Mad2+/− cells exhibit higher polyploidy
and less apoptosis than checkpoint-competent Mad2+/+ cells after pro-
longed treatment with KSP-IA or paclitaxel. Both lines were treated with
KSP-IA or paclitaxel for 48 hr, and then analyzed for DNA content by FACS.
The histograms of DNA content versus cell number are presented. The gray
open plot represents Mad2+/− cells and the black solid plot indicates
Mad2+/+ cells.
D: Mad2-haploinsufficiency enhances clonogenic survival following treat-
ment with KSP-IA. Both Mad2+/+ and Mad2+/− cells were treated with vehi-
cle or KSP-IA for 24 hr, and then cultured in drug-free medium for 10 days.
After fixation and staining with Giemsa, photos were taken and colonies
consisting of at least 50 cells were counted. The percentages of colonies
formed in drug-treated cells versus those formed in vehicle-treated cells
are presented. Cells were plated and treated in triplicate. Bars indicate SD.centrosomes and topologically abnormal DNA structures, which
might provoke cell demise by activating a p53-mediated G1
tetraploid checkpoint (Margolis et al., 2003). Under this hypoth-
esis, the requirement for prolonged KSP inhibition to induce55
A R T I C L EFigure 7. Prolonged inhibition of KSP activates Bax and initiates apoptosis
A and B: A2780 cells were treated with KSP-IA (300 nM) for 10 or 24 hr, and
either harvested immediately or incubated for another 24 hr in drug-free
medium prior to harvesting. Cells harvested immediately after drug treat-
ment were analyzed to determine the activation of Bax by immunoprecipi-
tation-coupled Western blot analysis and caspase-3-mediated cleavage
of PARP by Western blot (A). Cells harvested immediately after drug treat-
ment (indicated as 10 hr or 24 hr) or after a further incubation in the ab-
sence of KSP-IA (indicated as 10–24 hr or 24–24 hr) were analyzed for DNA
content by FACS (B).56Figure 8. Both activation of the spindle checkpoint and mitotic slippage
are required for activating Bax
A: HNB1 cells were incubated in the absence or presence of doxycycline
for 24 hr, and then treated with KSP-IA (300 nM) for 0, 16, or 24 hr. Cells
were analyzed for Bax activation, the steady-state levels of N-hBub1, and
cellular DNA content. The percentages of sub-G1 cells are shown.
B: HT29 cells were treated with KSP-IA for 28 hr, or exposed to KSP-IA for 24
hr followed by treatment with either DMSO or Purv (20 M) for 4 hr. The
activation of Bax, steady-state levels of p-nucleolin, mitotic index, and cel-
lular DNA content were determined.apoptosis could be explained by the fact that mitotic slippage
only occurs after sustained mitotic arrest in spindle check-
point-competent cells. Nevertheless, our data preclude this
possibility, since cells with weakened spindle checkpoint that
could more readily slip into pseudo-G1 phase after milder, if any,
mitotic arrest incur a much lower extent of apoptosis and ex-
hibit much greater clonogenic survival than the checkpoint-
proficient counterparts in response to KSP inhibition (Figures
5 and 6). In addition, facilitation of mitotic slippage promotes
apoptosis in spindle checkpoint-competent and slippage-
refractory HT29 cells that contain mutant p53 (Figures 4B and
4C). Several other p53-deficient cell lines, such as MDA-
MB468 (containing mutant p53) and HeLa (expressing HPV
E6), remain sensitive to KSP inhibitor-induced cell death, where
KSP-IA induced 25%–35% sub-G1 cells after 48 hr treatment,
which is comparable to the extent of apoptosis in KSP-IA-sen-
sitive cell lines containing wild-type p53, such as A2780. This
suggests that the induction of apoptosis following mitotic slip-
page may not depend on the p53-mediated tetraploid check-
point. Thus, mitotic slippage alone is not sufficient to trigger
apoptosis. Only activation of the spindle checkpoint followed
by mitotic slippage is able to initiate the apoptotic program. For
cells containing an intact spindle checkpoint, this mechanism
allows time for repairing spindle damages and eliminates cells
that can breach the spindle checkpoint.
Mitotic slippage by overriding an activated spindle check-
point may induce apoptosis by activating the proapoptotic pro-tein, Bax, since our data indicate that activation of the spindle
checkpoint followed by mitotic slippage induces Bax activation
(Figures 7 and 8). There are two possibilities to account for the
requirement for both activation of the spindle checkpoint and
mitotic slippage to induce apoptosis. First, activation of the
spindle checkpoint per se is proapoptotic, but this proapo-
ptotic activity is suppressed by antiapoptotic proteins that are
functional exclusively during mitosis. Mitotic slippage with
active spindle checkpoint results in the inactivation of anti-
apoptotic proteins and thereby triggers apoptosis. Consistent
with this hypothesis, it was recently shown that BubR1, a spin-
dle checkpoint protein, was proapoptotic (Shin et al., 2003) and
that survivin, an apoptotic inhibitor, was only active in mitosis
since its stability and activity are dependent on the mitotic ki-
nase Cdk1 (Li et al., 1998; O’Connor et al., 2000; Shin et al.,
2003). In this scenario, mitotic slippage with a high level of
BubR1 may result in the inactivation or elimination of survivin,
and thereafter BubR1 induces apoptosis. Whether the pro-
death BubR1 is responsible for Bax activation is worthy of fur-
ther investigation. Alternatively, the proapoptotic signal is not
generated until a breach of the spindle checkpoint. Since the
“SH3-only” proteins of the Bcl2 family are able to activate Bax
(Cory and Adams, 2002), it is of interest to compare their levels
and activity before and after the breach of spindle checkpoint.
As taxanes and other microtubule inhibitors also activate the
spindle checkpoint and cause mitotic arrest (Jordan et al.,
1993; Li and Benezra, 1996; Taylor and McKeon, 1997), they
could induce cell death by a mechanism that overlaps with that
of KSP inhibitors. Indeed, we found that paclitaxel-induced cell
death was linked to mitotic slippage as well (Figures 4B andCANCER CELL : JULY 2005
A R T I C L E4C), and that attenuation of the spindle checkpoint also re-
duced paclitaxel-induced apoptosis, although not to the same
extent as the suppression of KSP inhibitor-mediated lethality
(Figures 5C, 5D, and 6A–6C). This is consistent with several
recent reports (Chen et al., 2003; Sudo et al., 2004). Indeed, it
was shown that Purv synergized with paclitaxel in killing cancer
cells (O’Connor et al., 2002). However, unlike KSP inhibitors,
taxanes could potentially act on both mitotic and interphase
cells, depending on drug concentrations (Jordan et al., 1993;
Woods et al., 1995; Torres and Horwitz, 1998), and so it is likely
that taxanes can induce cell death through several mecha-
nisms.
This study provides useful guidance to the clinical develop-
ment of KSP inhibitors. Since both activation of the spindle
checkpoint and subsequent mitotic slippage are required for
inducing apoptosis, agents that can facilitate mitotic slippage
could act synergistically with KSP inhibitors in spindle check-
point-competent tumors. For example, sequential treatment
with a Cdk1 inhibitor may enhance the efficacy of KSP inhibi-
tors in slippage-refractory cancers. The finding that optimal
killing by a KSP inhibitor depends on an intact spindle check-
point could also impact clinical development of KSP inhibitors.
While complete loss of the spindle checkpoint function, such
as complete ablation of Mad2, is lethal in tumor cells (Kops et
al., 2004; Michel et al., 2004), partial loss of function causes
aneuploidy and contributes to tumorigenesis (Dai et al., 2004;
Hanks et al., 2004; Michel et al., 2004). Indeed, defects in the
spindle checkpoint are frequently seen in cancer cell lines, and
multiple factors, both genetic and epigenetic, could compro-
mise the spindle checkpoint (Cahill et al., 1998; Jin et al., 1998;
Wang et al., 2002; Anand et al., 2003; Hanks et al., 2004). Thus,
a strategy to evaluate the spindle checkpoint status in human
cancers would be useful for the identification of KSP inhibitor-
sensitive versus -resistant tumors, which is an important area
for future research.
Experimental procedures
Plasmid
The cDNA encoding the amino terminal domain of human Bub1 (N-hBub1,
amino acids 1–331) was isolated from RNAs extracted from HeLa cells by
reverse transcription polymerase chain reaction. It was cloned into the
pcDNA4/TO plasmid (Invitrogen) to generate pcDNA4/TO-N-hBub1. In this
construct, a Myc epitope tag is fused to the N terminus of N-hBub1, and the
expression of Myc-tagged N-hBub1 is under the control of two tetracycline
operators. The sequence of this construct was verified.
Cell lines, culture, and drug treatment
The HNB1 cell line was generated by transfection of REx HeLa cells with
N-hBub1 plasmid and selection for growth in the presence of Zeocin (100
g/ml) and Blasticidin (5 g/ml) using T-REx system (Invitrogen). The induc-
tion of N-hBub1 expression by tetracycline (2 g/ml) in HNB1 cells was
confirmed by Western blot using both anti-Myc and anti-Bub1 antibodies
(Santa Cruz).
A2780 cells were grown in RPMI1640 medium containing 10% fetal bo-
vine serum (FBS) and 10 g/ml insulin. HCT116 and HT29 cells were main-
tained in McCoy’s 5A medium supplemented with 10% FBS. For con-
tinuous drug exposure experiments, cells were treated with vehicle (0.1%
dimethylsulfoxide, DMSO), KSP-IA (300 nM), or paclitaxel (100 nM) (Sigma)
for various times, and harvested immediately after drug treatment for analy-
sis. For drug washout experiments, cells were treated with the vehicle or
KSP-IA for various times, and either harvested immediately or incubated for
a further 24 hr in the absence of the compound prior to harvesting.CANCER CELL : JULY 2005Cell synchronization
Cells were treated with 2 mM thymidine for 15 hr, followed by incubation in
the thymidine-free medium for 10 hr, and then treated again with 2 mM
thymidine for 15 hr. Cell synchronization at G1/S boundary was confirmed
by FACS. Blocked cells were released by incubation in thymidine-free me-
dium containing 10% FBS after three washings in phosphate-buffered sa-
line (PBS).
Flow cytometry/DNA content analysis
Both attached and floating cells were collected and fixed with 70% ethanol.
Cells were subsequently stained with 50 g/ml propidium iodide (PI) for 1
hr, and analyzed by FACS.
To determine the EC50 for KSP-IA to arrest cells in mitosis, A2780 cells
were incubated with vehicle or KSP-IA for 16 hr in a 7-point and half-log
dilution series. After drug treatment, cells were harvested and analyzed by
FACS to determine the percentage of cells containing 4N DNA.
Mitotic index
Cells were collected and fixed as described above. After treatment with a
blocking solution (PBS containing 0.2% w/v saponin and 0.2% BSA) for
1 hr, cells were incubated with the MPM2 monoclonal antibody (Upstate
Technology) in the block solution for 1 hr, followed by an incubation with
Alexa 488-conjugated goat against mouse IgG (Molecular Probes) for 1 hr.
Cells were analyzed by FACS and the percentage of cells stained by the
MPM2 antibody was designated as mitotic index.
Caspase-3 assay
After treatment (in triplicate) with the vehicle or KSP-IA for various times, the
caspase-3 activity in cell lysates was determined using ApoAlert Caspase
Fluorescent Assay kit (Clontech).
Western blot analysis
Cell pellets were lysed in RIPA buffer (50 mM Tris-HCl [pH 7.4], 1% IGEPAL,
and 1% sodium deoxycholate). Proteins in cell lysates were separated by
electrophoresis on 10% SDS-polyacrylamide gel (SDS-PAGE), transferred
to a PVDF membrane (Novex), immunostained, and visualized as described
(Tao et al., 2001). Anti-cyclin E, Bax, and Myc antibodies were purchased
from Santa Cruz Biotechnology, and antibodies recognizing phospho-
nucleolin, phosphohistone H3, BubR1, and GAPDH were obtained from Ap-
plied NeuroSolutions, Upstate Cell Signaling, BD Transduction Laborato-
ries, and Research Diagnostics, respectively. The caspase-3-mediated
cleavage of PARP is detected by a monoclonal antibody (Asp214) from
BD Pharmingen.
Immunofluorescence microscopy
After treatment with KSP-IA at 30 or 300 nM or vehicle for 16 hr, cells were
fixed, permeabilized, and immunostained as described (Tao et al., 2001).
Tubulin was stained by an anti-α-tubulin monoclonal antibody (clone DM1,
Sigma) (1:500) for 12 hr at 4°C, followed by incubation with FITC-conju-
gated donkey anti-mouse IgG for 1 hr at RT. After incubation with Hoechst
33342 (10 g/ml) for 10 min, slides were mounted. Mitotic spindles and
chromosomes were visualized by a fluorescence microscopy.
Detection of Bax conformational change (activation)
Both attached and floating cells were collected and lysed with Chaps lysis
buffer (10 mM Hepes [pH 7.4], 150 mM NaCl, and 1% Chaps). Cell lysates
containing 500 g protein were incubated with anti-Bax 6A7 monoclonal
antibody (Sigma) for 3 hr, followed by an incubation after adding protein G
agarose beads (Sigma) for 2 hr at 4°C. After washing in Chaps lysis buffer,
beads were boiled in 2× Tris-Glycine SDS sample buffer (Novex) and im-
mune complexes were subject to SDS-PAGE analysis. The Bax conformers
immunoprecipitated by the 6A7 antibody were detected by immunoblot
using an anti-Bax polyclonal antibody (Santa Cruz). The total amount of Bax
(input) in cell lysate was determined prior to immunoprecipitation.
Colony survival assay
Cells, seeded in triplicate at 10 or 3 × 103/well in 6-well plates and grown
overnight, were treated with 0.1% DMSO or KSP-IA (300 nM) for 24 hr. After
washing out the compound, cells were allowed to grow in drug-free medium
for 10 days, fixed with methanol, and stained by Giemsa. Following exten-57
A R T I C L Esive washing with H2O, photos were taken and colonies consisting of at
least 50 cells were scored.
Supplemental data
Supplemental data for this article can be found at http://www.cancercell.
org/cgi/content/full/8/1/49/DC1/.
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